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Abstract
Background: Clinical progression of colorectal cancers (CRC) may occur in parallel with distinctive signaling alterations. We
designed multidirectional analyses integrating microarray-based data with biostatistics and bioinformatics to elucidate the
signaling and metabolic alterations underlying CRC development in the adenoma-carcinoma sequence.
Methodology/Principal Findings: Studies were performed on normal mucosa, adenoma, and carcinoma samples obtained
during surgery or colonoscopy. Collections of cryostat sections prepared from the tissue samples were evaluated by a
pathologist to control the relative cell type content. The measurements were done using Affymetrix GeneChip HG-
U133plus2, and probe set data was generated using two normalization algorithms: MAS5.0 and GCRMA with least-variant
set (LVS). The data was evaluated using pair-wise comparisons and data decomposition into singular value decomposition
(SVD) modes. The method selected for the functional analysis used the Kolmogorov-Smirnov test. Expressional profiles
obtained in 105 samples of whole tissue sections were used to establish oncogenic signaling alterations in progression of
CRC, while those representing 40 microdissected specimens were used to select differences in KEGG pathways between
epithelium and mucosa. Based on a consensus of the results obtained by two normalization algorithms, and two probe set
sorting criteria, we identified 14 and 17 KEGG signaling and metabolic pathways that are significantly altered between
normal and tumor samples and between benign and malignant tumors, respectively. Several of them were also selected
from the raw microarray data of 2 recently published studies (GSE4183 and GSE8671).
Conclusion/Significance: Although the proposed strategy is computationally complex and labor–intensive, it may reduce
the number of false results.
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Introduction
Colorectal cancer (CRC) arises as a multi-step process of
successive cellular clone selection. As a result of the growth
advantage of dysplastic cells over their normal neighbors, the
morphological counterpart of molecular alterations leads to
progressive cytological and architectural derangement recogniz-
able as the adenoma-carcinoma sequence [1,2]. Recently, no more
than a dozen or so somatic ‘‘driver’’ mutations were established as
being responsible for CRC development [3,4]. However, tumors
exhibiting homogenous phenotypes share few mutated ‘‘cancer
genes’’; therefore, cancer complexity at the gene level is likely
reduced to a limited number of alterations within signaling and
metabolic pathways [5].
An individual cancer phenotype is the result of cell-specific,
developmental stage-specific, and metabolism-related changes in
gene expression selectively occurring at a time and modified by
epigenetic interactions [6]. With the introduction of high-density
DNA microarrays, an expectation of insight into the overall
molecular components of carcinogenesis has developed. Unfortu-
nately, a comparative analysis of microarray-based studies on
CRC development found rather weak overlap of the gene
expression profiles ([7] and the results section). These discrepan-
cies in the identified expression profiles may be due to technical
reasons, including the use of various microarray platforms,
different tissue collection methods, and numerous analytical
algorithms [7]. Although the rate of false assumptions might be
minimized by using an ‘‘optimal’’ analytical protocol, the selection
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13091of such protocol is still challenging [6]. Consequently, microarray
experiments allow for rough and mostly indirect assumptions.
Therefore, one may ask whether multidimensional and sub-
optimal microarray-based data can be applied to the study of
complex biological systems, including carcinogenesis.
To answer this question, microarray data originating from two
experimental procedures were analyzed by multiple methods
employed for identification of consensus differences in pathways
underlying CRC development through the adenoma-carcinoma
sequence. Samples of normal mucosa, adenomas, and carcinomas
obtained during surgery or colonoscopy were processed to select
differences between: (i) epithelium and mucosa in normal tissue
away from and directly adjacent to carcinoma, in adenoma and
carcinoma (using microdissected samples) and (ii) normal and
neoplastic tissues and adenomas and carcinomas (using whole
tissue sections). Finally, we addressed the potential and challenges
of translating microarray-based gene expression profiles into the
functional aspects of carcinogenesis.
Results
A total of 170 GeneChips were hybridized in this study. Twenty-
five of 130 arrays representing whole tissue section samples were
rejected from the data analyses. Twenty-four of these arrays were
rejected on the basis of poor GeneChip quality according to the
parameters established by Affymetrix and due to their internal
inconsistency with others as established by the principal component
analysis (PCA) (not shown). One microarray was rejected because of
mechanical damage. A parameter summary of 145 arrays of
suitable quality, 40 and 105 represented microdissected and whole
tissue section samples, respectively, is provided in Table S1.
From 54,675 probe sets of the Affymetrix HGU133plus2
microarray, 31,962 and 25,410 probe sets for whole tissue sections
and 29,242 and 24,002 probe sets for microdissected samples
passed the filtering procedure according to MAS5.0 and
GCRMA+ LVS algorithms, respectively. As shown in Figure S1,
the probe set signal distribution and levels extracted with the two
normalization algorithms significantly differed.
Signaling pathways distinguishing between colonic
epithelial cells and mucosa
Probe set selection from microarray data representing tissue
samples may be significantly affected by differences in the cell type
content of the normal and dysplastic mucosa (Table 1). Bearing
that in mind, we intended to define the consensus differences in
KEGG pathways which are more conserved between colonic
epithelial cells and mucosa than between normal and neoplastic
tissues. Gene expression profiles corresponding to tissue morphol-
ogy were established in pure colonic crypt epithelial cells (CEC)
and mucosa (MUC) (representing the epithelial cell layer and cell
content in lamina propria) which were captured from various parts
of the tumor consisting of invasive adenocarcinoma adjacent to
tubular adenoma with low grade dysplasia and from paired full-
thickness normal colon using the laser capture microdissection.
Data sets from these microdissected samples were analyzed in
the following pairs: CEC vs. MUC dissected from distant full-
thickness normal colon (NC), normal colon mucosa dissected from
tumor (NT), adenoma (AD), and carcinoma (CA). Pair-wise
comparisons were performed separately on microarray data sets
normalized by MAS5.0 and GCRMA+LVS algorithms. Probe sets
sorted according to significance of differentiation of CEC and
MUC in any pair set were used in Kolmogorov-Smirnov (K-S) test
to evaluate KEGG pathways alterations. The results of KEGG
annotations for each comparison are summarized in Table S2.
The pathways found in at least three of the four pair-wise
comparisons (Table 2) were considered to be distinguishing
between colonic epithelial cells and mucosa and were excluded
from the further selection of oncogenic signaling pathways.
Oncogenic signaling pathways
To establish oncogenic signaling distinguishing between normal
colon and neoplasms, data sets representing whole tissue sections
of normal colon, adenomas, and adenocarcinomas and normal-
ized by both MAS5.0 and GCRMA+LVS algorithms were
decomposed into major statistically independent variability modes
(supergenes) using singular value decomposition (SVD). We
assumed that SVD may establish some co-variations in gene
expression that could enable better definition of expression-based
functional alterations [8–10]. A graphic summary (Figure 1) of the
relationships between the samples revealed that the first and
strongest mode distinguished between normal colon and neoplastic
tissues, with one exception; tumors with lower malignant tissue
content (,35%) were grouped mainly with samples of normal
colon. This group of samples was discarded from the further pair-
wise comparisons. Lists of the probe sets sorted by both SVD and
gene-by-gene statistical testing are given in Table S3.
Table 1. The relative cell type content within normal and dysplastic mucosa used for laser capture microdissection (per 1 mm
2 of
the area).
Cell type Tissue sample type
Normal colon Normal colon dissected from tumor Adenoma Carcinoma
Epithelial cells (percent of total) 3183 (71.4%) 3032 (63.3%) 1650 (53.4%) 2330 (81.4%)
Fibroblasts 240 880 280 133
Lymphocytes 266 420 765 164
Intraepithelial lymphocytes 80 60 24 31
Plasmocytes 594 173 133 92
Granulocytes 20 26 37 35
Histocytes 47 40 78 45
Endothelial cells 26 160 120 33
Total 4456 4791 3087 2863
doi:10.1371/journal.pone.0013091.t001
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differentially expressed between normal and neoplastic tissues
were used for the calculation of their attribution to pre-defined
KEGG signaling pathways using the KS test, as summarized in
Figure 2. The distance of distribution was considered most
significant if the corrected p-value was less than 0.01 in at least one
data set normalized by either the MAS5.0 or GCRMA+LVS
algorithm, or if it was less than 0.05 in both data sets. The results
of selected KEGG annotations are shown in Table S4. The
KEGG signaling pathways derived from both gene expression
measurements and both lists of probe sets (selected by SVD and
pair-wise comparisons) seem to represent the most reliable findings
on molecular alterations between normal and neoplastic colon
tissue (Table 3).
Next, to estimate molecular alterations underlying tumor progres-
sion to malignancy, data sets representing whole tissue sections from
colonic neoplasms were decomposed into SVD modes (Figure S2)
a n da n a l y z e db yp a i r - w i s ec o m p a r i s o n s( T a b l eS 5 ) .P r o b es e t ss o r t e d
according to the first SVD mode and those differentially expressed
between adenomas and carcinomas were functionally analyzed by
annotation to the KEGG signaling pathway database (Table S6).
Again, the KEGG pathways were assumed to be the most
discriminative between benign and malignant colon tumors if they
were derived from the lists of probe sets selected by both SVD and
pair-wisecomparison (Table3).In general, they represented signaling
networks and cellular metabolism.
Testing oncogenic signaling in the colon adenoma-
carcinoma sequence by the use of the published
microarray data
Poor reproduction of microarrays by quantitative RT-PCR was
observed in this (not shown) and previously in independent studies
[11–13], likely as a consequence of the quite different methodol-
ogy used by these two techniques. Moreover, lack of proper
control analytical methods which would be considered as a ‘‘gold
standard’’ for functional analysis of microarray data unable direct
justification our assumption that the consensus pathways identified
by multiple analyses are more likely discriminative than those
identified by individual methods. Therefore, we asked a question
whether the consensus pathways can be also derived using the
proposed strategy from the readouts of the coherent studies.
We conducted normalization, summation and filtration of the
raw datasets provided by four recently published microarray-based
studies [14] (GSE8671, Sabates-Bellver et al.), [15] (GSE4183,
Galamb et al. 2008-1), [16] (GSE15960, Galamb et al. 2010), [17]
(GSE10714, Galamb et al. 2008-2), according to our processing
algorithm, independently of procedures applied by the respective
authors. Expectedly, although all four studies have analyzed colon
tumor transcriptomes using the same Affymetrix HGU133plus2
platform, there are less than 1/10 probe sets simultaneously
selected significant for all comparisons (Figure S3). Such a little
data reproducibility is a well known problem when tissue samples
Table 2. KEGG pathways found significant (KS test) in pair-
wise comparisons of pure colonic crypt epithelial cells (CEC)
and mucosa (MUC) in at least three of four sample groups:
normal colon (NC), normal tumor mucosa (NT), adenoma (AD),
and carcinoma (CA).
KEGG term NC NT AD CA
Cell adhesion molecules (CAMs) ++++
ECM-receptor interaction ++++
Focal adhesion ++++
Allograft rejection ++++
Autoimmune thyroid disease ++++
Complement and coagulation cascades ++++
Asthma ++++
Graft-versus-host disease ++++
Type I diabetes mellitus ++++
Leukocyte transendothelial migration ++++
Hematopoietic cell lineage ++++
Systemic lupus erythematosus ++++
Cytokine-cytokine receptor interaction +++2
Neuroactive ligand-receptor interaction +++2
Oxidative phosphorylation ++2 +
Pathogenic Escherichia coli infection – EHEC ++2 +
Antigen processing and presentation ++2 +
doi:10.1371/journal.pone.0013091.t002
Figure 1. Diagrams of the first statistically independent variability modes extracted from the original normalized with MAS5.0 (left
panels) and GCRMA+LVS (right panels) algorithms using SVD, uncovering the microarray data of the whole tissue section samples.
doi:10.1371/journal.pone.0013091.g001
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select the alternated KEGG signaling pathways, two probe-level processing procedures (MAS5.0 and GCRMA+LVS) in connection with two probe set
selection and sorting criterions (pair-wise comparison and SVD decomposition) were utilized. Selection of the KEGG signaling pathways was done
using the one-sided Kolmogorov-Smirnov test. To obtain the final results, KEGG intersection distinguishing between colonic epithelial cells and
mucosa (Table 2) was subtracted from intersection of KEGG annotation results for whole tissue section settings computed for the both comparisons.
doi:10.1371/journal.pone.0013091.g002
Table 3. KEGG terms corresponding to genes differentially expressed between normal colon samples with colonic neoplasms and
between adenomas and carcinomas.
Normal colon vs. colonic neoplasms Adenomas vs. adenocarcinomas
p53 signaling pathway p53 signaling pathway
Biosynthesis of unsaturated fatty acids Biosynthesis of unsaturated fatty acids
Proteasome Proteasome
Cell cycle Adherens junction
DNA replication TGF-beta signaling pathway
Purine metabolism PPAR signaling pathway
Pyrimidine metabolism Wnt signaling pathway
RNA polymerase Calcium signaling pathway
Aminoacyl-tRNA biosynthesis Colorectal cancer
Nucleotide excision repair Pancreatic cancer
Mismatch repair Bladder cancer
Base excision repair Valine, leucine, and isoleucine degradation
Homologous recombination Fatty acid metabolism
Folate biosynthesis Tryptophan metabolism
Sphingolipid metabolism
Arachidonic acid metabolism
Axon guidance
doi:10.1371/journal.pone.0013091.t003
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various conditions.
Next, to test the potential of the proposed analytical procedure
in identification of consensus signaling alterations, we employed
the microarray data provided by Galamb et al. (GSE4183) [15]
and Sabates-Bellver et al. (GSE8671) [14]. Samples in those
studies were handled in similar way as in our experiment with the
whole tissue sections. As shown in Table 4 (and Table S7), the
multidirectional computations selected 11 out of 14 consensus
KEGG pathways, which distinguished normal colon and neo-
plasms in our data sets, also from the GSE4183 data set. Similar
KEGG pathways selection was obtained by multiple analyses
performed on the GSE8671 data set which established transcrip-
tomes of normal colon and adenomas. This time, 3 of 4
procedures used for data normalization and probe set sorting
allowed identifying 11 consensus signaling pathways consistent
with those selected in our studies (Table 4), although none
common signaling pathways were found when the GSE8671 data
set was normalized with the GCRMA+LVS algorithm and probe
sets were sorted by the statistic of pair-wise comparison.
KEGG signaling pathways related to cell cycle, DNA
replication, purine metabolism, pyrimidine metabolism, RNA
polymerase, proteasome, aminoacyl-tRNA biosynthesis, mismatch
repair and nucleotide excision repair were selected in both our and
two recently published microarray-based studies.
In contrast to nearly full agreement described above, only one
out of 17 KEGG pathways, Axon guidance, discriminating between
adenomas and adenocarcinomas (Table 5), has been found
significant for the GSE4183 data set (Table S7). On the other
hand, several pathways extracted by our procedure from the
GSE4183 data set were common with the KEGG pathways
distinguishing between colonic epithelial cells and mucosa in our
data sets (Table 5, and Table S7).
Gene expression diagnostic for the progression to CRC
Gene expression signature that can be employed for diagnostic
purposes should consist of probe sets with signal progressively
increased or decreased over the normal tissue-adenoma-carcinoma
sequence. To select CRC progression markers, the procedure was
consistently applied to analyze data sets obtained by two tissue
handling procedures. Probe sets with gradually increasing or
decreasing expression (p,0.01, FDR adjusted) throughout CRC
progression that were found in all three sample sets (whole tissue
sections, microdissected epithelial cells, and microdissected
mucosa) are presented in Table 6 and 7, respectively. Of these
probe sets, a few were representative for data sets normalized with
both algorithms.
The level of these probe sets appeared to be significantly altered
also in other microarray studies [14–16] (Table S7). Nine, 14 and
15 of them were found to significantly differentiate NC and AD or
NC and CA (FDR,0.01 and FC.1.5) in two studies conducted
by Galamb et al. [16] [15] and Sabates-Bellver et al. [14],
respectively.
Discussion
Carcinogenesis is a microevolutionary process that results from
a series of genetic and epigenetic alterations. As a consequence of
the successive rounds of mutation and selection of cell clones,
molecular alterations affect the fundamental processes of a normal
cell, such as proliferation, differentiation, and apoptosis [1].
Though multiple proto-oncogenes and tumor suppressor genes
play an essential role in neoplastic growth, no more than 15
somatic ‘‘driver’’ mutations are thought to be responsible for
individual cancer initiation, progression, and maintenance.
However, among a group of clinically homogenous tumors, only
a few mutated ‘‘cancer genes’’ are shared [3,4]. These highly
variable patterns of somatic mutations in cancer genomes are
likely responsible for biological differences among cancers. On the
Table 4. Comparison of KEGG pathways distinguishing
between normal colon samples and colonic neoplasms
selected from our and two published microarray data.
This study
GSE4183 NC
vs. AD+CA
GSE8671
NC vs. AD
Cell cycle + +
DNA replication + +
Purine metabolism + +
Pyrimidine metabolism + +
RNA polymerase + +
p53 signaling pathway +/2* +
Proteasome ++
Aminoacyl-tRNA biosynthesis ++
Mismatch repair ++
Nucleotide excision repair ++
Base excision repair ++ /2*
Homologous recombination + -
Folate biosynthesis - +
Biosynthesis of unsaturated fatty acids - -
*KEGG terms selected only from data sets normalized with MAS5.0.
doi:10.1371/journal.pone.0013091.t004
Table 5. KEGG terms corresponding to genes differentially
expressed between adenomas and carcinomas.
Whole tissue sections
Adherens junction
p53 signaling pathway
PPAR signaling pathway
Wnt signaling pathway
Calcium signaling pathway
TGF-beta signaling pathway
Axon guidance
Colorectal cancer
Pancreatic cancer
Bladder cancer
Proteasome
Valine, leucine, and isoleucine degradation
Fatty acid metabolism
Tryptophan metabolism
Sphingolipid metabolism
Biosynthesis of unsaturated fatty acids
Arachidonic acid metabolism
doi:10.1371/journal.pone.0013091.t005
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that lead to standard treatment algorithms.
Most CRCs arise in a progression through adenoma to
carcinoma phenotypes as a consequence of altered genetic
information. Because genetic information is utilized by macro-
molecules (RNA and proteins) and metabolites representing short-
term storage, selectively provided at the time and grouped into
signaling and metabolic pathways, cancer complexity at the gene
level is likely reduced to a limited number of altered pathways.
Thus, the clinical progression of colon tumor phenotypes may
occur in parallel to distinctive signaling alterations [5].
Several microarray-based studies in CRC have been performed
[18,19], most to identify discriminative gene expression profiles for
diagnostic and prognostic purposes [17,20–29]. Some other
studies were performed to identify molecular processes underlying
tumorigenesis and metastasis [30–35]. However, a comparative
analysis of the above mentioned studies revealed rather weak
overlap of catalogued gene expression profiles [7], which is mostly
a consequence of microarray experiments generating large sets of
data that are not directly interpretable. As a result, significant data
pre-processing is required to convert raw data (images of the
scanned chips) into meaningful biological knowledge. The analysis
of a typical microarray experiment involves the following steps: 1)
image processing, 2) probe-level processing aimed at the
generation of gene-expression summaries and minimizing techni-
cal variability introduced during sample preparation and mea-
surement, 3) statistical analysis that, depending on the scientific
goal of the experiment, may be focused on grouping genes with
similar expression, identifying genes differentially expressed
between two or more experimental conditions, or discovering
unknown subclasses of samples correlating with the phenotype or
clinical course, and 4) higher level (functional) analysis, which
allows for biological interpretation of the results. Notably, no fully
acceptable protocol exists for microarray data processing, and the
different methods used for subsequent stages of the analysis
pipeline may result in substantially different results. Therefore, the
Table 6. Genes with gradually increasing expression (p,0.01, FDR adjusted) through CRC progression in all three sample sets.
Up-regulated
GCRMA_LVS MAS5.0
227140_at 227140_at
Tribbles homolog 3 (Drosophila) Tribbles homolog 3 (Drosophila)
Collagen, type XII, alpha 1 Collagen, type XII, alpha 1
Solute carrier family 39 (zinc transporter), member 10 Solute carrier family 39 (zinc transporter), member 10
Diaphanous homolog 3 (Drosophila) Diaphanous homolog 3 (Drosophila)
Jub, ajuba homolog (Xenopus laevis) Jub, ajuba homolog (Xenopus laevis)
Stearoyl-CoA desaturase (delta-9-desaturase) Stearoyl-CoA desaturase (delta-9-desaturase)
p53 and DNA damage-regulated 1 p53 and DNA damage-regulated 1
Collagen, type IV, alpha 1 Aminopeptidase-like 1
Collagen, type I, alpha 2
Hypothetical LOC541471
General transcription factor IIIA
Nnicotinamide N-methyltransferase
Phosphoprotein enriched in astrocytes 15
Solute carrier family 7 (cationic amino acid transporter, y+ system), member 5
Chromosome 13 open reading frame 3
Core-binding factor, beta subunit
Regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 1
RecQ protein-like (DNA helicase Q1-like)
Glucosamine-6-phosphate deaminase 1
Proteasome maturation protein
Breast cancer 2, early onset
Ubiquitin D
Nuclear factor (erythroid-derived 2)-like 3
Phosphoglucomutase 3
Tryptophanyl-tRNA synthetase
CCAAT/enhancer binding protein (C/EBP), beta
Hypothetical protein MGC15523
Calumenin
Transmembrane protease, serine 3
Chemokine (C-X-C motif) ligand 11
Probe set names are given where no gene name is available.
doi:10.1371/journal.pone.0013091.t006
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biological information in the samples, but of the choices made
during data processing. The problem of an extensive data
transformation results in a situation in which we cannot always
justify the biological meaning of a particular readout, and
adjustment of the final results to the working hypothesis may
introduce systemic bias and, in the end, manipulate the results.
We aimed to identify the essential oncogenic signaling in CRC.
Because there is no method that allows the direct estimation of
changes in cellular signaling on the genomic scale, we applied an
integrative genomics approach that may connect gene expression
profiles with molecular pathway alterations. The assessments were
directed to minimize the number of prior assumptions and
arbitrary choices made during data processing, particularly in the
two steps known to have the most severe impact on the results of
the analysis: probe-level processing and selection of differentially
expressed genes.
Several probe-level processing methods have been proposed,
including MAS5.0 [36], MBEI [37], RMA [38], and GCGMA
[39]. Although this stage of the analysis pipeline is often simply
referred to as normalization, it usually involves three separate
steps: background adjustment, normalization, and summarization.
Background adjustment is aimed at removing the influence of the
optical noise, autofluorescence of the chip surface, non-specific
binding, and cross-hybridization from the measured signal. Next,
probe intensities are normalized in order to allow direct
comparisons between chips and minimize the technical variation
that results from possible differences in total mRNA quantities or
unequal efficiencies in labeling and hybridization. Finally, in the
summarization step, the adjusted and normalized intensities in
each probe set are combined into a single numerical value that
represents the relative abundance of a transcript in the sample.
The reliable evaluation of the performance of low-level
processing methods is not an easy task because it requires prior
knowledge of the data properties, especially which genes are truly
differentially expressed. Consequently, most of the published
comparisons of low-level processing algorithms rely on an RNA
spike-in or dilution datasets [40–43]. Because the true expression
ratios are known in such datasets, they can easily be used to study
the bias (accuracy) and variance (precision) of the gene expression
estimations derived by different methods. However, though
artificially generated datasets are potentially useful validation
tools, there might be some doubt as to whether they actually
represent the characteristics of the data from typical microarray
experiments in terms of the fraction of differentially expressed
genes or RNA quality. Furthermore, the spike-in and dilution data
consist of technical replicates, and thus do not reflect the true
biological variability between samples from typical data sets.
Despite numerous efforts [44], there are still no widely accepted
methods for assessing the effectiveness of low-level processing for a
particular real-world dataset.
To avoid the arbitrary choices in expression summary
generation and data normalization, all presented analyses have
been carried out using two algorithms: MAS5.0 and GCRMA
combined with LVS normalization [45]. MAS5.0 is a relatively
simple algorithm that processes a single chip at a time, utilizing
probe position on the chip and mismatch (MM) probes to correct
the perfect match (PM) probe signal readout. Normalization is
performed after the summarization step by global scaling so that
the trimmed mean intensities of the arrays to be compared are
identical. GCRMA takes into the account the GC content of the
probe and conducts normalization on a full set of microarrays.
GCRMA does not utilize the MM probe signal. The LVS
algorithm normalizes the data set based on the least variant probe
sets and replaces the quantile normalization implemented in
GCRMA.
As expected, the use of two different algorithms resulted in data
sets with considerably different distributions of normalized relative
expression values. Therefore, to maximize reliability, both data
sets were used in further analyses. In addition, we filtered out low-
expression probe sets that, due to unfavorable signal-to-noise ratio,
were likely to be a source of false positives.
Another factor strongly affecting the final results of microarray
data analysis is the method used to define differentially expressed
Table 7. Genes with gradually decreasing expression (p,0.01, FDR adjusted) through CRC progression in all three sample sets.
Down-regulated
GCRMA_LVS MAS5.0
Hypothetical protein FLJ21511 (220724_at; 220723_s_at) Hypothetical protein FLJ21511 (220724_at; 220723_s_at)
Protein kinase, cAMP-dependent, catalytic, beta Protein kinase, cAMP-dependent, catalytic, beta
Hypothetical protein LOC253012 Hypothetical protein LOC253012
protein kinase, cAMP-dependent, catalytic, beta Protein kinase, cAMP-dependent, catalytic, beta
UDP glucuronosyltransferase 1 family, polypeptide A1 UDP glucuronosyltransferase 1 family,polypeptide A1
Ring finger protein 125 Ring finger protein 125
UDP glucuronosyltransferase 1 family, polypeptide A6 UDP glucuronosyltransferase 1 family, polypeptide A6
B-cell CLL/lymphoma 2 B-cell CLL/lymphoma 2
Zinc finger and BTB domain containing 7C 227630_at
Hypothetical protein LOC92482 Nuclear receptor subfamily 3, group C, member 2
CAS1 domain containing 1 Sterile alpha motif domain containing 13
Somatostatin receptor 1 Similar to all-trans-13,14-dihydroretinol saturase
Abhydrolase domain containing 3 Programmed cell death 4 (neoplastic transformation inhibitor)
Bestrophin 2 N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits
UDP glucuronosyltransferase 1 family, polypeptide A9
Probe set names are given where no gene name is available.
doi:10.1371/journal.pone.0013091.t007
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ranging from simple methods using only the fold change criterion
to more sophisticated approaches using permutation-based
statistical testing [46] or a Bayesian probabilistic framework
[47]. However, with most of the methods it is necessary to specify
strict criteria a gene must meet to be considered differentially
expressed, for example, FDR thresholds and/or fold change.
Various criteria produce substantially different lists of genes as the
basis of further biological conclusions. Furthermore, such methods
assume an unambiguous assignment of the samples to the classes
representing experimental conditions, which is not always the case.
The existence of subclasses with different expression profiles (e.g.,
a tumor with low amount of carcinoma) may alter the feature
selection process and mislead further functional analyses of
differentially expressed genes.
In order to overcome the mentioned limitations of typical
feature selection procedures, we used an approach that combines
supervised statistical testing with an unsupervised method, which
does not require prior knowledge of sample attribution.
The method selected for the functional analysis used the K-S
test. In contrast to common over-representation methods, the test
does not require arbitrary cut-off criterion for studied probe sets.
The significance of gene sets is determined based on their position
on a sorted list of all genes present in the assay. Here, sorting was
based on either the p-values of a statistical test in a pair-wise
comparison (supervised method) or the contribution to a selected
SVD component (unsupervised method). Such methodology
requires only one arbitrary cut-off: the adjusted p-value designat-
ing the significance of a given gene set.
The gene set dictionary selected for analysis was KEGG. Each
set consists of the genes involved in a physiological process. Most
of the KEGG subsets contain genes that interact with each other;
thus, the structure of the database, in contrast to Gene Ontology
(GO), is ‘‘flat’’. No relationship between the specified pathways
simplifies the correction for multiple hypothesis testing. The
number of categories in the KEGG database is a factor of 100 less
than GO (,200 vs. ,30,000). Therefore, the chance of a false
positive result is significantly less when the KEGG database is used
and less strict correction for multiple hypothesis testing is required.
In this study, pathways were selected as significant based on a
consensus of the results obtained with two normalization
algorithms, and two probe set sorting criterions. In whole tissue
sections we identified 14 and 17 KEGG signaling and metabolic
pathways significantly altered between normal colon and colon
tumors and between benign and malignant tumors, respectively.
Altogether, cell proliferation and differentiation, the regulation of
gene expression, DNA repair, cell growth and survival, the
signaling (TGF-beta, Wnt, PPAR, Calcium) pathways, aminoacids
and lipids metabolism may be considered the predominant
alterations, appearing on different levels of molecular interaction
and reaction networks of oncogenic signaling in the colon.
Using microdissected tissues, a considerable set of pathways
have been selected which differentiate between epithelia and
mucosa, regardless of the disease stage. Of these pathways, a wide
array of biological processes, including antigen processing and
presentation, immune response, and adaptive inflammatory host
defenses, cell migration, cell-cell and cell-matrix adhesion, clearly
differentiated functions attributed to cells forming the epithelial
layers from those of the resident immune cells infiltrating the
lamina propria. Several KEGG pathways distinguishing between
microdissected colonic epithelial cells and mucosa were also
selected from comparisons between whole tissue sections of
adenomas and adenocarcinomas (Table S6).
Results of NC - AD/CA comparisons in our dataset are, in
general, in good concordance with such comparisons performed
on datasets provided by Galamb et al. (GSE4183) [15] and
Sabates-Bellver et al. (GSE8671) [14]. On the other hand, there is
little overlap between the former of those studies and our dataset
for AD - CA comparison. Notably, several pathways found as
relevant in GSE4183 dataset were found to be differentiating
epithelia and mucosa (Table 5) in our study. However, paper by
Galamb et al. does not provide details on sample cellular
composition and without an access to the histological assessment
of tissues enrolled to microarray studies further result comparison
between different studies may be possible only to some extent.
There are over 80 KEGG pathways found significant when all
comparisons from publicly available data are taken into account.
This, and the fact that there are no "standard" protocols for
functional analysis of microarray experiments could lead to tuning
the analysis procedure to fit the expected results. We regard that
such pitfall could be avoided by selecting the intersection of results
acquired with multiple protocols as proposed in this study.
To date, a variety of methods have been used to dissect the
tissue of interest, as well as RNA extraction and amplification
protocols and algorithms for data normalization and significant
features selection. Thus, any variation in the procedure introduces
difficulties in the direct comparison of the results. Consistent with
this idea, probe sets with the same signal level alterations,
regardless of the sample handling protocol applied, are of
particular interest. Genes found to be differentially expressed
between normal colon, adenoma, and carcinoma can be used as
markers of the progression process. If the differences are
progressive, the interpretation of the results is straightforward;
the higher the difference detected, the more advanced the
carcinogenesis.
We found 17 probe sets with both attributes: significant
(FDR,0.01) progressive signal level changes in the NC R AD
R CA sequence for microdissection and whole tissue section
collected samples, and for MAS5.0 and GCRMA+LVS normal-
ization (Table 6 and 7). Eight of the probe sets were progressively
up-regulated (Table 6) and nine were down-regulated (Table 7).
Expression of most of these probe sets were also found to be
changed in other microarray studies [14–16].
In summary, microarray-based gene expression profiles were
applied to describe gene regulatory networks appearing on
different levels of molecular interaction and reaction networks
forming oncogenic signaling in the colon. Although some of the
KEGG pathways selected in our analyses may result from
differences in the proportion of epithelial and stromal cells excised
from adenomas and carcinomas, these studies highlighted
significant differences in the molecular makeup of adenomas and
adenocarcinomas related to oncogenic signaling. However, though
the changes in patterns of individual probe sets annotated to
defined KEGG signaling pathways intuitively fit predictions, the
microarray data could be translated into the functional aspects of
carcinogenesis only as indirect annotations.
The lack of independent methods of verification of functional
annotations to expression profiles makes the final conclusions from
microarray readouts prone to the subjective selection of biostatis-
tical tools. We proposed to tackle this problem by using a wide
range of computational methods. Although this strategy is
computationally complex and labor–intensive, it reduces the
fraction of false results. Herein, we provided an example of such
a multidirectional algorithm directed for maximizing the reliability
of microarray data results. On the other hand, with such strict
conditions, only highly reliable biological processes are selected.
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concordance of published results justifies the applied conditions.
The main disadvantage of the proposed functional analysis
relates to the assumption that the number of affected genes within
a single pathway determines the degree of its alteration. This
assumption may be correct for most metabolic pathways that rely
on the mass-action law [48] but may not hold true for signaling
pathways. In fact, the universal number of genes altered in a single
pathway to consider the pathway as affected remains unknown.
Consequently, the lack of knowledge about the compensation
effect and its extent makes such analyses incomplete. If so, the full
discovery and understanding of biological processes underlying
CRC on a genomic scale would be possible only with a more
stringent approach, which requires an extensive knowledge of
signaling mechanisms in all biological processes considered. This
approach is not feasible with the currently available bioinformatics
tools.
Materials and Methods
Ethics Statement
Patients were prospectively selected for the study between
January and December 2006 at the Department of Gastroenter-
ology and Hepatology and the Department of Colorectal Cancer,
Cancer Center-Institute, Warsaw. The study protocol was
approved by the Cancer Center Bioethics Committee, and all
patients signed informed consent before inclusion.
Sporadic colonic carcinomas were obtained by surgical
resection through laparotomy, and one to four tumor fragments,
depending on the tumor’s size, and two fragments of paired full-
thickness normal colon were cut. Colonic adenomas were obtained
during colonoscopic polypectomy, and one to three adenoma
fragments, depending on the polyp’s size (0.8–3.0 cm), were cut
from the tip of each polyp immediately after removal. The amount
of removed polyp did not interfere with the histological diagnosis.
All carcinoma and polyp tissue specimens were collected by
pathologists using the same procedure. In addition, three biopsies
were taken from the normal colonic mucosa of 7 healthy subjects
who underwent screening colonoscopy using large biopsy forceps.
All tissue specimens were snap frozen in liquid nitrogen within 10–
30 min of harvesting and stored at 272uC until use.
The clinical characteristics of patients and histopathology of
analyzed tissue samples are presented in Table S8.
Microdissected samples
Frozen tissue specimens were cut as a series of 6-mm thick
cryosections and mounted on a polyethylene naphthalate (PEN)
membrane slide and dehydrated for 2 min in 70% ethanol and
5 min in 100% ethanol. Subsequently, tissue sections were stained
in 5% (w/v) alcoholic solution of cresyl violet, rinsed in 100%
ethanol, and the slides air-dried for 15 min. The interested areas
were independently isolated from the slides using the PALM laser
microdissection and pressure catapulting (LMPC) system (PALM
MicroBeam with PALM RoboMover module and PALM
RoboSoftware; Carl Zeiss MicroImaging GmbH, Germany).
Microdissected samples from different parts of the tumor and
normal colon were pooled in separate microtubes, immediately
lysed with 100 ml RTL buffer (Qiagen GmbH, Hilden, Germany)
containing 1% b-mercaptoethanol, and stored at 272uC.
To obtain suitable reproducibility and reliability of the
estimations, tissue samples were dissected by LCM of five
replicates for each type of epithelial cell and mucosa from one
colon tumor and the paired full-thickness normal colon.
Independent microdissections of epithelial cell layers yielded an
average of 2.8 mm
2 of total captured area (range 2.1–3.5 mm
2),
whereas captured mucosa that represented a normal or neoplastic
epithelial layer with an absent lamina propria of the muscularis
mucosae yielded an average 13 mm
2 of total area (range 10–
15 mm
2). The relative cell type content within normal and
dysplastic mucosa estimated per 1 mm
2 is presented in Table 1.
Whole tissue sections
Several series of cryostat sections were prepared from different
parts of each specimen using a Microm HM 505E (Zeiss,
Germany). Upper and lower sections from each cryosection
collection were evaluated by the pathologist to control the relative
cell type content. RNA was isolated from those cryostat sections
representing a given tissue specimen which contained the highest
percentage of epithelial cells.
Histological evaluation of the examined tissues revealed a
median relative content of 60% (range 18–98%) normal mucosa in
surgically obtained normal colon specimens and 90% (28–99%)
and 55% (15–98%) dysplastic mucosa in specimens representing
benign and malignant colon tumors, respectively (Table S8).
Endoscopic biopsies from the normal colons represented mostly
mucosa. Thirty-one polyps were identified as tubular adenomas,
and 14 as tubulo-villous adenomas; 42 and 3 adenomas exhibited
low-grade and high-grade dysplasia, respectively. Altogether, the
whole tissue section samples represented 45 colon adenomas, 36
adenocarcinomas, and 24 normal colon samples, of which 7 were
obtained during screening colonoscopies, 14 were taken from the
full-thickness normal colon at least 5 cm distant from adenocar-
cinoma, and 3 represented normal mucosa directly adjacent to the
neoplastic tissues.
RNA extraction and amplification
Total RNA was isolated from whole tissue sections and
microdissected tissue samples using the RNeasy Plus Mini Kit
and QIAshredder columns and the RNeasy Plus Micro Kit
(Qiagen GmbH, Hilden, Germany), respectively. RNA samples
were checked for quality on the Agilent 2100 Bioanalyzer. Each
sample used for further microarray analysis presented distinct
peaks corresponding to intact 28S and 18S ribosomal RNA.
Five micrograms of total RNA isolated from each whole tissue
section sample and 10–50 ng of total RNA isolated from
microdissected samples were used as starting material for the
synthesis of biotin-labeled cRNA with one and two rounds of
amplification using One-cycle and Two-cycle Target Labeling and
Control Reagents (Affymetrix), respectively, the latter with the
MEGAscript High Yield Transcription Kit (Ambion Inc, Austin
USA). The biotin-labeled cRNA was purified using RNeasy spin
columns, fragmented, and hybridized on Affymetrix oligonucleo-
tide microarrays (GeneChip HG-U133plus2).
Gene expression microarray analysis
To measure gene expression, probe set data (cell intensity files)
were generated using two standard normalization algorithms:
Affymetrix Microarray Suite v.5 (MAS5.0) and GCRMA with
least-variant set (LVS) probe sets. The calculations were performed
using R/BioConductor (version 2.8.1) packages affy (version
1.20.2), gcrma (version 2.14.1), and FLUSH.LVS.bundle (version
1.2.1, proportion=0.6). For data filtration, we selected the probe
sets with signal intensity above the threshold limit in at least 5% of
samples. The threshold was established at the 98th percentile of the
expression levels from Y-chromosome–linked probe set signals
detectable in female samples. In addition, the probe sets with signal
FC higher than 1.5 (in relation to median) in less than 6 samples
were removed from whole tissue sections dataset.
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groups, both gene-by-gene statistical testing using the permutation
test with t statistics and singular value decomposition (SVD) of the
data matrix were employed. Because experimental variability is
common among microarray data sets, the p-values were adjusted
for multiple hypothesis testing using the Benjamini-Hochberg
procedure [49] to control the false discovery rate (FDR). Probe sets
sorted according to either the adjusted p-values of the t-test or the
contribution of a selected SVD mode were assigned to Kyoto
Encyclopedia of Genes and Genomes (KEGG) Pathways.
The one-sided Kolmogorov-Smirnoff test (KS test) was used to
calculate whether probe sets attributed to a particular signaling
pathway located closer to the top of the lists than expected by
chance. Next, the resulting p-values were corrected for testing
multiple hypotheses. We considered the alterations in KEGG
pathways as most significant if the adjusted KS test p-values
derived from both orderings (by the pair wise test statistic and
SVD) were less than 0.01 in at least one data set normalized by
either the MAS5.0 or GCRMA+LVS algorithm, or if the adjusted
p-value was less than 0.05 in both data sets.
Statistical and functional analyses were performed using
proprietary software working in MATLAB (R2009a, MathWorks)
and R/Bioconductor environments.
The same workflow was applied for external datasets: GSE4183
and GSE8671. The threshold for data filtration was established on
the same level as for our ‘‘whole tissue section’’ dataset. Probe sets
with signal level higher that threshold in less than 5 and 6 samples
(GSE4183, GSE8671 respectively) were filtered out.
Supplementary data
Supplementary data and all MIAME compliment microarray
data are available at Gene Expression Omnibus (GSE20916).
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=bhervmw
uqemiyra&acc=GSE20916
Supporting Information
Figure S1 Distribution of probe set signals. (A,B) Histograms
of signals extracted from microdissected samples using MAS5.0
and GCRMA+LVS, respectively. (C,D) Histograms of signals
extracted from macrodissected samples using MAS5.0 and
GCRMA+LVS, respectively.
Found at: doi:10.1371/journal.pone.0013091.s001 (0.18 MB
PDF)
Figure S2 Diagrams of the first SVD modes representing
macrodissected adenomas (red) and carcinomas (blue); data
normalized by MAS5.0 (left panels) and GCRMA+LVS (right).
Found at: doi:10.1371/journal.pone.0013091.s002 (0.05 MB
PDF)
Figure S3 Venn diagram presenting numbers of probe sets
differentiating normal colon (NC) mucosa and adenoma (AD) (left
panel) or normal colon and colorectal cancer (CRC) (right panel)
in a given studies. Data was normalized with GCRMA+LVS.
Difference was considered significant if FDR in permutation test
was less than 0.05.
Found at: doi:10.1371/journal.pone.0013091.s003 (0.06 MB
PDF)
Table S1 Summary of the quality parameters of individual
arrays. Analyzed parameters were established by Affymetrix for
GeneChip hybridization with cRNA synthesized by one- or two-
cycle amplification procedures.
Found at: doi:10.1371/journal.pone.0013091.s004 (0.28 MB
DOC)
Table S2 Significant KEGG terms selected by K-S test
according to lists of probe sets sorted by p-value in pair-wise
comparisons of pure colonic crypt epithelial cells (CEC) and
mucosa (MUC) dissected from normal colon (NC), normal mucosa
adjusted to neoplastic tissue (NT), adenoma (AD) and carcinoma
(CA).
Found at: doi:10.1371/journal.pone.0013091.s005 (0.06 MB
DOC)
Table S3 Lists of the probe sets sorted either by contribution to
a selected SVD component or p-value in pair-wise comparisons for
the whole tissue section samples. Provided as zipped excel file.
Found at: doi:10.1371/journal.pone.0013091.s006 (3.46 MB ZIP)
Table S4 The summary of the significance of differential
representation of KEGG terms according to lists sorted by
contribution to a selected SVD component or p-value in pair-
wise comparisons of microarray data of whole tissue section
samples.
Found at: doi:10.1371/journal.pone.0013091.s007 (0.07 MB
DOC)
Table S5 Probe sets sorted according to the p-value in pair-wise
comparisons between benign and malignant whole tissue sections
of colonic neoplasms.
Found at: doi:10.1371/journal.pone.0013091.s008 (3.59 MB
XLS)
Table S6 Summary of the significance of the differential
representation of KEGG pathways selected by the K-S test from
probe sets lists sorted either by contribution to a selected SVD
component or p-value in pair-wise comparison of whole tissue
sections of adenoma (AD) and carcinoma (CA) samples.
Found at: doi:10.1371/journal.pone.0013091.s009 (0.07 MB
DOC)
Table S7 Significant KEGG pathways for comparing normal
colon samples with colonic neoplasms and adenomas with
adenocarcinomas in GSE4183 and GSE8671 datasets.
Found at: doi:10.1371/journal.pone.0013091.s010 (0.03 MB
XLS)
Table S8 Patient clinical characteristics and histopathology of
analyzed tissue samples.
Found at: doi:10.1371/journal.pone.0013091.s011 (0.18 MB
DOC)
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